Bambevi
Bevacizumab biosimilar developed by Apotex. Reference product Avastin.
Brands by market: Bambevi (Canada) · Commercial partner or holder: Apotex
FDAnot listed
EMAnot listed
PMDAnot listed
HCSep 2021approved
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Bambevi
Health CanadaApprovedBrand
Bambevi
Holder or applicant
Apotex INC
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Sep 2021
Application or permission
DIN 02520729, 02520737
Presentations
100, 400 mg
Source
S022
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- HCSep 2021Notice of Compliance, Health Canada
Sources
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.